144 related articles for article (PubMed ID: 12963171)
1. Continuous intrauterine compared with cyclic oral progestin administration in perimenopausal HRT.
Boon J; Scholten PC; Oldenhave A; Heintz AP
Maturitas; 2003 Sep; 46(1):69-77. PubMed ID: 12963171
[TBL] [Abstract][Full Text] [Related]
2. Transdermal estrogen with a levonorgestrel-releasing intrauterine device for climacteric complaints: clinical and endometrial responses.
Raudaskoski TH; Lahti EI; Kauppila AJ; Apaja-Sarkkinen MA; Laatikainen TJ
Am J Obstet Gynecol; 1995 Jan; 172(1 Pt 1):114-9. PubMed ID: 7847516
[TBL] [Abstract][Full Text] [Related]
3. Intrauterine 10 microg and 20 microg levonorgestrel systems in postmenopausal women receiving oral oestrogen replacement therapy: clinical, endometrial and metabolic response.
Raudaskoski T; Tapanainen J; Tomás E; Luotola H; Pekonen F; Ronni-Sivula H; Timonen H; Riphagen F; Laatikainen T
BJOG; 2002 Feb; 109(2):136-44. PubMed ID: 11888095
[TBL] [Abstract][Full Text] [Related]
4. A comparative study of the effects of an estradiol-releasing vaginal ring combined with an oral gestagen versus transdermal estrogen combined with a levonorgestrel-releasing IUD: clinical findings and endometrial response.
Kalogirou D; Antoniou G; Karakitsos P; Kalogirou O; Antoniou D; Giannikos L
Int J Fertil Menopausal Stud; 1996; 41(6):522-7. PubMed ID: 9010746
[TBL] [Abstract][Full Text] [Related]
5. Long-term compliance of continuous combined estrogen and progestogen replacement in postmenopausal women.
Dören M; Schneider HP
Maturitas; 1996 Oct; 25(2):99-105. PubMed ID: 8905600
[TBL] [Abstract][Full Text] [Related]
6. Intrauterine or oral administration of levonorgestrel in combination with estradiol to perimenopausal women--effects on lipid metabolism during 12 months of treatment.
Andersson K; Stadberg E; Mattsson LA; Rybo G; Samsioe G
Int J Fertil Menopausal Stud; 1996; 41(5):476-83. PubMed ID: 8934257
[TBL] [Abstract][Full Text] [Related]
7. Serum lipids and lipoproteins in postmenopausal women receiving transdermal oestrogen in combination with a levonorgestrel-releasing intrauterine device.
Raudaskoski TH; Tomás EI; Paakkari IA; Kauppila AJ; Laatikainen TJ
Maturitas; 1995 Jun; 22(1):47-53. PubMed ID: 7666816
[TBL] [Abstract][Full Text] [Related]
8. Intrauterine administration of levonorgestrel 5 and 10 microg/24 hours in perimenopausal hormone replacement therapy. A randomized clinical study during one year.
Wollter-Svensson LO; Stadberg E; Andersson K; Mattsson LA; Odlind V; Persson I
Acta Obstet Gynecol Scand; 1997 May; 76(5):449-54. PubMed ID: 9197448
[TBL] [Abstract][Full Text] [Related]
9. Transdermal estrogen with a levonorgestrel-releasing intrauterine device for climacteric complaints versus estradiol-releasing vaginal ring with a vaginal progesterone suppository: clinical and endometrial responses.
Antoniou G; Kalogirou D; Karakitsos P; Antoniou D; Kalogirou O; Giannikos L
Maturitas; 1997 Mar; 26(2):103-11. PubMed ID: 9089559
[TBL] [Abstract][Full Text] [Related]
10. Percutaneous estradiol gel with an intrauterine levonorgestrel releasing device or natural progesterone in hormone replacement therapy.
Suvanto-Luukkonen E; Sundström H; Penttinen J; Läärä E; Pramila S; Kauppila A
Maturitas; 1997 Apr; 26(3):211-7. PubMed ID: 9147353
[TBL] [Abstract][Full Text] [Related]
11. The endometrial response to sequential and continuous combined oestrogen-progestogen replacement therapy.
Sturdee DW; Ulrich LG; Barlow DH; Wells M; Campbell MJ; Vessey MP; Nielsen B; Anderson MC; Bragg AJ
BJOG; 2000 Nov; 107(11):1392-400. PubMed ID: 11117768
[TBL] [Abstract][Full Text] [Related]
12. A low-dose start in hormone replacement therapy provides a beneficial bleeding profile and few side-effects: randomized comparison with a conventional-dose regimen.
Mattsson LA; Skouby SO; Heikkinen J; Vaheri R; Mäenpää J; Timonen U
Climacteric; 2004 Mar; 7(1):59-69. PubMed ID: 15259284
[TBL] [Abstract][Full Text] [Related]
13. A randomized, double-blind, multicentre study comparing the clinical effects of two sequential estradiol-progestin combinations containing either desogestrel or norethisterone acetate in climacteric women with estrogen deficiency symptoms.
Saure A; Hirvonen E; Milsom I; Christensen A; Damber MG
Maturitas; 1996 May; 24(1-2):111-8. PubMed ID: 8794442
[TBL] [Abstract][Full Text] [Related]
14. Intrauterine release of levonorgestrel--a new way of adding progestogen in hormone replacement therapy.
Andersson K; Mattsson LA; Rybo G; Stadberg E
Obstet Gynecol; 1992 Jun; 79(6):963-7. PubMed ID: 1579323
[TBL] [Abstract][Full Text] [Related]
15. Comparing the effects of intrauterine progestin system and oral progestin on health-related quality of life and Kupperman index in hormone replacement therapy.
Pirimoglu ZM; Ozyapi AG; Kars B; Buyukbayrak EE; Solak Y; Karsidag AY; Unal O; Turan MC
J Obstet Gynaecol Res; 2011 Oct; 37(10):1376-81. PubMed ID: 21599801
[TBL] [Abstract][Full Text] [Related]
16. Randomised comparative trial of the levonorgestrel intrauterine system and norethisterone for treatment of idiopathic menorrhagia.
Irvine GA; Campbell-Brown MB; Lumsden MA; Heikkilä A; Walker JJ; Cameron IT
Br J Obstet Gynaecol; 1998 Jun; 105(6):592-8. PubMed ID: 9647148
[TBL] [Abstract][Full Text] [Related]
17. Continuous, combined hormone replacement: randomized comparison of transdermal and oral preparations.
Mattsson LA; Bohnet HG; Gredmark T; Torhorst J; Hornig F; Hüls G
Obstet Gynecol; 1999 Jul; 94(1):61-5. PubMed ID: 10389719
[TBL] [Abstract][Full Text] [Related]
18. Plasma insulin-like growth factor-I and its binding proteins 1 and 3 during continuous nonoral and oral combined hormone replacement therapy.
Raudaskoski T; Knip M; Laatikainen T
Menopause; 1998; 5(4):217-22. PubMed ID: 9872487
[TBL] [Abstract][Full Text] [Related]
19. Insulin-like growth factor-binding protein-1: a biochemical marker of endometrial response to progestin during hormone replacement therapy.
Suvanto-Luukkonen E; Sundström H; Penttinen J; Kauppila A; Rutanen EM
Maturitas; 1995 Nov; 22(3):255-62. PubMed ID: 8746884
[TBL] [Abstract][Full Text] [Related]
20. Intrauterine levonorgestrel delivered by a frameless system, combined with systemic estrogen: acceptability and endometrial safety after 3 years of use in peri- and postmenopausal women.
Wildemeersch D; Janssens D; Schacht E; Pylyser K; de Wever N
Gynecol Endocrinol; 2005 Jun; 20(6):336-42. PubMed ID: 16019384
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
